News

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in

Many products sold by companies aren't must-have items. However, healthcare is a necessity. And the healthcare sector is poised to grow over the next decade and beyond with aging populations around

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating for

In today's video, I discuss Advanced Micro Devices (NASDAQ: AMD) and my thoughts for the upcoming year. To learn more, check out the short video, consider subscribing, and click the special offer

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2

In this video, I will cover the recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong underlying business prospects that they're practically unstoppable.

Three

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for

In this video, I will cover the recent updates regarding Advanced Micro Devices (NASDAQ: AMD). Watch the short video to learn more, consider subscribing, and click the special offer link below.

One of the more high-profile electric vehicle (EV) stocks on the scene, pickup and SUV manufacturer Rivian Automotive (NASDAQ: RIVN), had a fine Thursday on the stock exchange. Investors traded the

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q4 2024 Earnings CallJan 16, 2025, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of UnitedHealth Group (NYSE: UNH) were pulling back Thursday after the company delivered underwhelming fourth-quarter results, as sales were weaker than expected and its costs rose.

 As of

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while

Telecom giant AT&T (NYSE: T) has been steadily gaining wireless and fiber internet subscribers over the past few years. Over the two-year period that ended on Sept. 30, AT&T grew its total wireless

It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much.

However, there are

Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period. Instead, as long-term investors know, the key is to

It's tempting to try and pick stocks that you think might double or triple in value in a year or two. However, the best gains often come over the long term, and sometimes they can come in unexpected

Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024, according to data from S&P Global Market Intelligence.

Summit was an early-stage biotechnology stock heading into the

Medicine is the cornerstone of healthcare. That remains true today, with a global pharmaceutical industry valued at $1.4 trillion and expected to grow at 6.1% annually through 2030. In this light

Dividend stocks trading at discounted prices can make for great investments if you're willing to be patient. That's because, assuming their payouts are sustainable, you can lock in a higher yield

Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning